文献速递肝病

采用一目了然的一线试验逐步算法无创诊断进展期肝纤维化与肝硬化

A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis.
PubMed 文献 · J Hepatol · 2017-01-12

该诊断研究纳入3754例经肝活检的慢性肝病患者,按2:1随机分为推导集与验证集,开发并验证了基于年龄、性别、γ-谷氨酰转移酶、天冬氨酸氨基转移酶、血小板和凝血酶原时间的简易肝纤维化试验(eLIFT)。验证集中eLIFT与FIB4敏感性相同(78.0% vs 76.6%,p=0.470),但eLIFT假阳性更少,尤其在≥60岁患者中(53.8% vs 82.0%,p<0.001)。eLIFT-FMVCTE算法对进展期肝纤维化敏感性76.1%,对肝硬化敏感性92.1%。

要点

  • eLIFT为基于年龄、性别、γ-谷氨酰转移酶、天冬氨酸氨基转移酶、血小板和凝血酶原时间的一目了然评分。
  • 验证集中eLIFT与FIB4敏感性相同(78.0% vs 76.6%,p=0.470),但eLIFT假阳性更少。
  • eLIFT-FMVCTE算法对进展期肝纤维化敏感性76.1%,对肝硬化敏感性92.1%。

核心结论

  • eLIFT-FMVCTE算法将进展期肝纤维化的检测扩展至所有慢性肝病患者,并减少无显著慢性肝病患者的非必要肝科转诊。

研究设计与样本

  • 诊断研究:3754例经肝活检的慢性肝病患者按2:1随机分为推导集与验证集。
  • 预后研究:对1275例有基线纤维化检测的慢性肝病患者进行纵向随访。

主要发现

  • 验证集中eLIFT与FIB4敏感性相同(78.0% vs 76.6%,p=0.470),但eLIFT假阳性更少,尤其在≥60岁患者中(53.8% vs 82.0%,p<0.001)。
  • 在评估的八种纤维化检测中,FibroMeter联合振动控制瞬时弹性成像(VCTE)准确性最高。
  • eLIFT-FMVCTE算法(一线eLIFT,二线FibroMeterVCTE)对进展期肝纤维化敏感性为76.1%,对肝硬化敏感性为92.1%。
  • 预后研究中,经算法诊断为「无/轻度纤维化」的患者肝脏相关预后极佳,无需转诊肝科医生。

关键数值与推荐

  • eLIFT评分项目包括年龄、性别、γ-谷氨酰转移酶、天冬氨酸氨基转移酶、血小板和凝血酶原时间。

临床怎么用

  • eLIFT作为一线检测筛选需进一步FibroMeterVCTE评估的高危患者,eLIFT-FMVCTE算法识别需转诊专科的进展期慢性肝病患者及可留在常规医生处照护的无或轻度肝损伤患者。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Chronic liver diseases (CLD) are common, and are therefore mainly managed by non-hepatologists. These physicians lack access to the best non-invasive tests of liver fibrosis, and consequently cannot accurately determine the disease severity. Referral to a hepatologist is then needed. We aimed to implement an algorithm, comprising a new first-line test usable by all physicians, for the detection of advanced liver fibrosis in all CLD patients. METHODS: Diagnostic study: 3754 CLD patients with liver biopsy were 2:1 randomized into derivation and validation sets. Prognostic study: longitudinal follow-up of 1275 CLD patients with baseline fibrosis tests. RESULTS: Diagnostic study: the easy liver fibrosis test (eLIFT), an "at-a-glance" sum of points attributed to age, gender, gamma-glutamyl transferase, aspartate aminotransferase (AST), platelets and prothrombin time, was developed for the diagnosis of advanced fibrosis. In the validation set, eLIFT and fibrosis-4 (FIB4) had the same sensitivity (78.0% vs. 76.6%, p=0.470) but eLIFT gave fewer false positive results, especially in patients ≥60years old (53.8% vs. 82.0%, p<0.001), and was thus more suitable as screening test. FibroMeter with vibration controlled transient elastography (VCTE) was the most accurate among the eight fibrosis tests evaluated. The sensitivity of the eLIFT-FMVCTE algorithm (first-line eLIFT, second-line FibroMeterVCTE) was 76.1% for advanced fibrosis and 92.1% for cirrhosis. Prognostic study: patients diagnosed as having "no/mild fibrosis" by the algorithm had excellent liver-related prognosis with thus no need for referral to a hepatologist. CONCLUSION: The eLIFT-FMVCTE algorithm extends the detection of advanced liver fibrosis to all CLD patients and reduces unnecessary referrals of patients without significant CLD to hepatologists. LAY SUMMARY: Blood fibrosis tests and transient elastography accurately diagnose advanced liver fibrosis in the large population of patients having chronic liver disease, but these non-invasive tests are only currently available in specialized centers. We have developed an algorithm including the easy liver fibrosis test (eLIFT), a new simple and widely available blood test. It is used as a first-line procedure that selects at-risk patients who need further evaluation with the FibroMeterVCTE, an accurate fibrosis test combining blood markers and transient elastography result. This new algorithm, called the eLIFT-FMVCTE, accurately identifies the patients with advanced chronic liver disease who need referral to a specialist, and those with no or mild liver lesions who can remain under the care of their usual physician. CLINICAL TRIAL REGISTRATION: No registration (analysis of pooled data from previously published diagnostic studies).

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Boursier J, de Ledinghen V, Leroy V, et al. A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis. J Hepatol. 2017. PMID: 28088581. doi:10.1016/j.jhep.2017.01.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。